DXCM Nov 2024 190.000 call
| Previous Close | 3.9700 |
| Open | 3.9700 |
| Bid | 1.0500 |
| Ask | 1.1500 |
| Strike | 190.00 |
| Expire Date | 2024-11-15 |
| Day's Range | 3.9700 - 3.9700 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 19 |
Business WireDexcom Expands AID Partnership Into The Netherlands
EDINBURGH, Scotland, June 20, 2024--DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, today announced that people living with Type 1 diabetes in the Netherlands will be able to use a new tubeless Hybrid Closed Loop system (HCL) the Omnipod® 5 integrated with the Dexcom G6 Continuous Glucose Monitor (CGM), for an easier1-3 diabetes management experience. In the Netherlands, 100,000 people have type 1 diabetes, with an estimated 10,00
Business WireDexcom Showcases Extensive Clinical Data at ADA 2024 Demonstrating the Benefit of Dexcom CGM Use Among People With Type 2 Diabetes
SAN DIEGO, June 20, 2024--DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, will showcase its expanding focus on Dexcom CGM use among people with Type 2 diabetes, the launch of the Omnipod 5 Automated Insulin Delivery System with Dexcom G7 and its relentless commitment to innovation at the 84th Scientific Sessions of the American Diabetes Association conference held June 21–24, 2024, in Orlando.
Barrons.comNew Weight-Loss Drugs and Devices Are Coming This Week
Weight-loss breakthroughs all emerged from diabetes treatment. Meetings such as the coming American Diabetes Association are increasingly dominated by news on obesity drugs.
